| Gestational age at RAL initiation (weeks, days) |
Reason for Raltegravir Use |
VL at RAL initiation (copies/mL) |
ARV drugs during pregnancy |
Gestational age at delivery (weeks, days) |
Exposure to RAL (days) |
VL at delivery (copies/mL) |
Decline of VL (log) from RAL initiation to delivery |
| 38,4 |
Rapid viral suppression |
5,613 |
FTC+TDF+ATV/r+RAL |
39, 3 |
6 |
<20 |
2.45 |
| 38,4 |
Rapid viral suppression |
96, 557 |
FTC+TDF+LPV/r+RAL |
37, 3 |
6 |
30, 84 |
1.50 |
| 37,5 |
Rapid viral suppression |
351,321 |
ZVD+3TC+LPV/r+RAL |
38, 6 |
8 |
7, 74 |
1.70 |
| 21,1 |
Transaminitis from LPV/r |
20,670 |
FTC+TDF+RAL |
40, 1 |
133 |
- |
3.01 |
| 31,1 |
Rapid viral suppression |
61,496 |
ZVD+3TC+RAL |
38, 1 |
49 |
911 |
1.83 |
| 39,6 |
Rapid viral suppression |
71,660 |
FTC+TDF+ LPV/r+RAL |
40, 2 |
2 |
13,717 |
0.72 |
| 33,3 |
Rapid viral suppression |
201 |
FTC+TDF+ LPV/r+RAL |
34, 1 |
5 |
66 |
0.48 |
| 35,0 |
Rapid viral suppression |
321 |
FTC+TDF+LPV/r+RAL |
36,2 |
9 |
26 |
1.09 |
|
